CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma

• Status: Recruiting
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is to determine the maximum tolerated dose(MTD) and recommened phase 2 dose(RP2D) based on dose limiting toxicity(DLT), and to evaluate safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Lenalidomide and Dexamethasone in patients with Previously Treated Multiple Myeloma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical
• Treatments: BB 1101; CKD-581; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Lenalidomide; Thalidomide

Criteria

Inclusion Criteria:

• must have received at least two prior lines of therapy and Diagnosis of symptomatic multiple myeloma(IMWG 2015)

• Eastern Cooperative Oncology Group performance status ≤ 2

• Life expectancy 12 weeks

• must have the following laboratory values within 3 weeks prior to first dose of study drug

• absolute neutrophil count(ANC) ≥ 1,500 mm3

• platelet count(PLT)≥ 100,000 mm3

• Hb ≥ 9.0g/dL

• AST(SGOT) and ALT(SGPT) ≤ 3 x upper limit of normal(UNL)

• Serum bilirubin ≤ 1.5 x ULN (but, Gilbert syndrome ≤ 3 x UNL)

• Creatinin Clearance(CrCl) ≤ 50mL/min

• One more measureable disease following values

• Serum M-protein ≥ 1g/dL

• Urine M-Protein ≥ 200mg/24hr

• in that case serum M-protein, urine M-Protein nonmeasurable and FLC ratio abnormal, Serum free light chain(FLC) level ≥ 100mg/L(≥10mg/dL)

• more than 24 weeks prior to last lenalidomide dose

• must have signed the consent form

Exclusion Criteria:

• Patients with CNS disease

• Patients with clinically significant heart disease within 24weeks prior to first dose of study drug

• patients with clinically significans abnormal EKG, echocardiography at screening

• patients with patients with embolism within 24 weeks

• patients with active hepatitis, HIV positive(exception, non active hepatitis)

• peripheral neuropathy ≥ CTCAE grade 2 within 2 weeks prior to first dose of study drug

• Patients with clinically significant disease

• Patients with a prior malignancy with in the last 3 years except adequately treated basal cell or squamous cell or skin cancer, in situ cervical cancer

• Patients who have received surgery, chemotherapy, radiation therapy or immunotherapy or any other investigational drugs ≤ 4 weeks prior to first dose of study drug and during treatment period

• Patients who can not anticoagulate

• Patients who have received dexamethasone >10mg/day within 2week prior to first dose of study drug and during treatment period

• Women who are pregnant or breast feeding or women of childbearing potential not using an effective method of birth control. Male patients whose sexual partners are not using effective birth control.

• patients with hypersensitive reaction of lenalidomide or dexamethasone